Posted by Michael Wonder on 09 Sep 2024
First cancer medicine decision following PHARMAC funding boost
9 September 2024 - PHARMAC has decided to widen access to two medicines for several types of cancer.
Pembrolizumab (Keytruda) will be funded from 1 October 2024 for eligible people with advanced triple-negative breast cancer, head and neck cancer, colorectal cancer, bladder cancer, and Hodgkin lymphoma. Nivolumab (Opdivo) will be funded from 1 November for eligible people with kidney cancer.
